AUROPHARMA.NS Cash Flow
Aurobindo Pharma Ltd.
Profit & Loss Balance Sheet Cash Flow
Cash Flow · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Net Cash from Operating Activities | ₹23.87 Bn | ₹24.35 Bn | ₹39.25 Bn | ₹55.26 Bn | CashFlowsFromUsedInOperatingActivities |
| Net Cash from Investing Activities | ₹-39.78 Bn | ₹-42.56 Bn | ₹-18.75 Bn | ₹-34.58 Bn | CashFlowsFromUsedInInvestingActivities |
| Net Cash from Financing Activities | ₹18.14 Bn | ₹8.00 Bn | ₹1.20 Bn | ₹-12.69 Bn | CashFlowsFromUsedInFinancingActivities |
| Effect of Exchange Rate Changes | ₹-0.00 Bn | ₹0.14 Bn | ₹0.09 Bn | ₹8.29 Bn | EffectOfExchangeRateChangesOnCashAndCashEquivalents |
| Net Increase/(Decrease) in Cash | ₹2.23 Bn | ₹-10.07 Bn | ₹21.78 Bn | ₹16.28 Bn | IncreaseDecreaseInCashAndCashEquivalents |
| Cash and Cash Equivalents (Closing) | ₹41.69 Bn | ₹43.92 Bn | N/A | N/A | CashAndCashEquivalentsCashFlowStatement |
Every figure above is the exact value of the named XBRL element from AUROPHARMA.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).